Your browser is too old
We can't provide a great video experience on old browserUpdate now
Irritable bowel disease
In this lecture ´´Treatment of Bowel Diseases´´ are explained. Section one is about ´´irritable bowel disease´´. Initially, irritable bowel syndrome is focused. Then drugs used to treat IBS are discussed. This is followed by elucidation of serotonin 5-HT3-receptor antagonists. Alongside its pharmacokinetics is pursued. Likewise, mechanism of action is illustrated. Clinical use and adverse effects are elaborated later on.
Antispasmodics and ca2+ channel activators
Section two is about ''Antispasmodics and Ca2+ Channel Activators''. First theme of discussion is antispasmodics drugs. Next is the elucidation of antispasmodics. This is followed by explanation of antispasmodics (anticholinergics). After that pharmacodynamics is discussed. Furthermore, chloride channel activator is pursued. Subsequently, mechanism of action comes under consideration. Then information about its pharmacodynamics, clinical use, and toxicity is delivered.
Inflammatory bowel disease
Section three is about ''Inflammatory Bowel Disease''. Educator's prime focus is the elucidation of inflammatory bowel disease. Then drugs used to treat inflammatory bowel disease are categorized. Subsequently, therapeutic pyramid approach to IBD is pursued. Later on, aminosalicylates are discussed. Moreover, available formulations are explained. Afterwards, sites of 5-ASA release from formulations are highlighted. Next theme of discussion is azo compounds. Educator also talks about mesalamine compounds. This is followed by its pharmacokinetics, clinical use, and adverse effects.
Glucocorticoids and purine analogue
Section four is about ''Glucocorticoids and Purine Analogue''. Educator’s first theme of discussion is glucocorticoids - prednisone and prednisolone. After that hydrocortisone is pursued. This is followed by budesonide. Then clinical use and adverse effects are reported. Next focus is on purine analogues. Moreover, its pharmacokinetics, clinical use, and adverse effects are discussed in succession. At last, educator highlights drug interactions.
Methotrexate and antitumor necrosis factor
Section five is about ''Methotrexate and Antitumor Necrosis Factor''. Educator begins by discussing methotrexate along with elucidation of pharmacokinetics, clinical use, and ADRs. After that antitumor necrosis factor therapy is explained comprehensively. Then clinical use is discussed. Likewise, adverse effects come under consideration. Moving onward, anti integrin therapy is covered in this part. Concluding comments are given on vedolizumab.